Dr. Gordon J. Freeman on Toxicities Associated With Immunotherapies
Freeman says when a patient is given chemotherapy, oncologists can anticipate certain toxicities and treat accordingly. With immunotherapies, Freeman says the toxicities are associated with immune attacks where there shouldn't be any. These attacks can result in side effects such as skin rashes, colitis, and neumonitis.
Gordon J. Freeman, PhD, professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School, discusses the expanding realm of immunotherapies and what toxicities medical professionals should expect. Freeman says when a patient is given chemotherapy, oncologists can anticipate certain toxicities and treat accordingly. Immunotherapies are associated with a different set of toxicities, such as skin rashes, colitis, and pneumonitis, which oncologists need to be aware of.
Freeman adds that these immunotherapies are generally administered in short, tolerable time frames and usually result in lower toxicities for patients.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
